PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.08%
Both companies show declining cash positions (-1.08% vs AGEN's -40.36%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
Below half of AGEN's -28.66%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
Below half of AGEN's -25.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
Below half of AGEN's -17.97%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-18.62%
Less than half of AGEN's 9.10%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.73%
1.25-1.5x AGEN's -13.37%. Martin Whitman is wary of bigger short-term burdens.
20.52%
Less than half of AGEN's -6.90%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.52%
Less than half of AGEN's -3.41%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
6.94%
Less than half of AGEN's -4.27%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.13%
0.75-0.9x AGEN's -2.72%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
-79.29%
Above 1.5x AGEN's -19.46%. Michael Burry suspects a significant bump in 'other' equity items vs. competitor.
-7.18%
Below half AGEN's -28.35%. Michael Burry sees potential underperformance in building shareholder capital.
-1.08%
Below half AGEN's -17.97%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
20.52%
Less than half of AGEN's -6.88%. David Dodd sees less overall debt expansion vs. competitor.
21.53%
Above 1.5x AGEN's 11.95%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.